Skip to main content
logo
GSK plc (GLAXF)
OTCMKTS · Delayed Price · Currency is USD
27.23
0.00 (0.00%)
Mar 9, 2026, 9:30 AM EST

Revenue

Millions GBP. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
HIV Revenue
7.69B7.09B
HIV Revenue Growth
8.44%10.01%
Respiratory, Immunology and Inflammation Revenue
3.81B3.30B
Respiratory, Immunology and Inflammation Revenue Growth
15.49%9.06%
Oncology Revenue
1.98B1.41B
Oncology Revenue Growth
40.21%92.89%
Specialty Medicines Revenue
13.47B11.81B
Specialty Medicines Revenue Growth
14.09%15.29%
Shingles Revenue
3.56B3.36B
Shingles Revenue Growth
5.77%-2.38%
Meningitis Revenue
1.58B1.44B
Meningitis Revenue Growth
10.16%14.05%
Influenza Revenue
303.00M408.00M
Influenza Revenue Growth
-25.74%-19.05%
Established Vaccines Revenue
3.12B3.34B
Established Vaccines Revenue Growth
-6.56%2.23%
Vaccines Revenue
9.16B9.14B
Vaccines Revenue Growth
0.21%-7.36%
Respiratory Revenue
7.07B7.21B
Respiratory Revenue Growth
-2.01%5.68%
Other General Medicines Revenue
2.97B3.22B
Other General Medicines Revenue Growth
-7.68%-5.30%
General Medicines Revenue
10.04B10.43B
General Medicines Revenue Growth
-3.76%2.04%
Total Commerical Operations Revenue
32.67B31.38B
Total Commerical Operations Revenue Growth
4.12%3.46%
Revenue (Total)
--

Revenue by Geography

Millions GBP. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
US Revenue
16.86B16.38B
US Revenue Growth
2.90%3.56%
Europe Revenue
7.53B6.67B
Europe Revenue Growth
13.01%1.55%
International Revenue
8.28B8.33B
International Revenue Growth
-0.61%4.81%
Revenue (Total)
--

EBIT

Millions GBP. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Commercial Operations Segment Profit
16.26B15.34B
Commercial Operations Segment Profit Growth
6.03%4.63%
Research & Development Segment Profit
-6.25B-5.85B
Operating Income (Other)
-2.08B-5.47B
Operating Income (Total)
7.93B4.02B
Operating Income (Total) Growth
97.26%-40.38%
Updated Dec 31, 2025. Data Source: Fiscal.ai.